Fresenius Kabi in talks to buy Akorn

By Gareth Macdonald contact

- Last updated on GMT


Related tags: U.s. securities and exchange commission, Fresenius kabi

Akorn Inc is in takeover talks with German injectable drug specialist Fresenius SE & Co. KGaA.

The US generic drug manufacturer confirmed the talks in a US Securities and Exchange Commission (SEC) filing​ today.

Similarly, Fresenius said​ discussions are ongoing.

A spokesman for the German firm told us "Fresenius Kabi is currently in discussions with Akorn, Inc. concerning a potential acquisition​."

He declined to comment further.

Related news

Show more

Related products

Local lab Data Management

Local lab Data Management

Q2 Solutions | 01-May-2020 | Data Sheet

When a clinical trial requires local or point-of-care laboratory testing, managing the resulting data can be a significant burden to both the sponsor and...

Q2 Solutions: Corporate Brochure

Q2 Solutions: Corporate Brochure

Q2 Solutions | 17-Apr-2020 | Product Brochure

We are an innovative, progressive and responsive partner with the global experience, medical expertise and focus on quality that is integral to drug, medical...

Follow us


View more